Chunghwa Chemical Synthesis & Biotech Co Ltd - Asset Resilience Ratio
Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) has an Asset Resilience Ratio of 0.21% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 1762 liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2023)
This chart shows how Chunghwa Chemical Synthesis & Biotech Co Ltd's Asset Resilience Ratio has changed over time. See 1762 net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Chunghwa Chemical Synthesis & Biotech Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Chunghwa Chemical Synthesis & Biotech Co (1762) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$10.70 Million | 0.21% |
| Total Liquid Assets | NT$10.70 Million | 0.21% |
Asset Resilience Insights
- Limited Liquidity: Chunghwa Chemical Synthesis & Biotech Co Ltd maintains only 0.21% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Chunghwa Chemical Synthesis & Biotech Co Ltd Industry Peers by Asset Resilience Ratio
Compare Chunghwa Chemical Synthesis & Biotech Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Chunghwa Chemical Synthesis & Biotech Co Ltd (2009–2023)
The table below shows the annual Asset Resilience Ratio data for Chunghwa Chemical Synthesis & Biotech Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.21% | NT$10.70 Million ≈ $337.11K |
NT$5.17 Billion ≈ $162.94 Million |
+0.44pp |
| 2022-12-31 | -0.23% | NT$-10.70 Million ≈ $-337.11K |
NT$4.56 Billion ≈ $143.80 Million |
+0.01pp |
| 2021-12-31 | -0.24% | NT$-10.70 Million ≈ $-337.11K |
NT$4.38 Billion ≈ $138.02 Million |
+0.10pp |
| 2020-12-31 | -0.34% | NT$-10.70 Million ≈ $-337.11K |
NT$3.15 Billion ≈ $99.15 Million |
-0.03pp |
| 2019-12-31 | -0.31% | NT$-10.70 Million ≈ $-337.11K |
NT$3.44 Billion ≈ $108.34 Million |
+0.02pp |
| 2018-12-31 | -0.33% | NT$-10.70 Million ≈ $-337.11K |
NT$3.22 Billion ≈ $101.49 Million |
-0.02pp |
| 2017-12-31 | -0.31% | NT$-10.70 Million ≈ $-337.11K |
NT$3.45 Billion ≈ $108.63 Million |
+0.08pp |
| 2016-12-31 | -0.39% | NT$-10.70 Million ≈ $-337.11K |
NT$2.73 Billion ≈ $85.87 Million |
-0.02pp |
| 2015-12-31 | -0.37% | NT$-10.70 Million ≈ $-337.11K |
NT$2.87 Billion ≈ $90.44 Million |
-0.04pp |
| 2014-12-31 | -0.33% | NT$-10.70 Million ≈ $-337.11K |
NT$3.21 Billion ≈ $101.05 Million |
-1.39pp |
| 2012-12-31 | 1.05% | NT$31.76 Million ≈ $1.00 Million |
NT$3.02 Billion ≈ $95.00 Million |
+1.04pp |
| 2010-12-31 | 0.02% | NT$422.00K ≈ $13.30K |
NT$2.37 Billion ≈ $74.68 Million |
+0.00pp |
| 2009-12-31 | 0.02% | NT$351.00K ≈ $11.06K |
NT$2.31 Billion ≈ $72.85 Million |
-- |
About Chunghwa Chemical Synthesis & Biotech Co Ltd
Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the research, development, manufacturing, and sale of active pharmaceutical ingredients in Taiwan, the United States, India, Greece, Croatia, Japan, and internationally. The company offers antifungal, immunosuppressant, oncology, cardiovascular, peptide drug, immunomodulating agents, statin, muscle relaxant, ACE inhibitor with complete DM… Read more